A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2017
At a glance
- Drugs Temozolomide (Primary) ; Antineoplastics
- Indications Astrocytoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 May 2013 Planned end date changed from 1 Oct 2012 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 03 Aug 2012 Planned end date changed from 1 Oct 2009 to 1 Oct 2012 as reported by ClinicalTrials.gov.